Brian Gladsden, Mosaic Therapeutics CEO
April 4, 2023 07:00 AM EDT
Financing
Startups

Ex­clu­sive: On­col­o­gy start­up from Sanger In­sti­tute nabs $28M, ex-No­var­tis SVP as CEO

Kyle LaHucik

Senior Reporter

The Well­come Sanger In­sti­tute’s lat­est on­col­o­gy spin­out will en­ter the clin­ic in about 18 to 24 months with a new CEO at the helm and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times